Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’
Source: Patrick Trucchio  (7/15/22)
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with alcohol use disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD. More >

Pharma Co. Reduces Mortality Rates by 70% in ALS Trial
Source: Streetwise Reports  (7/15/22)
Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial. More >

Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial
Source: Streetwise Reports  (7/14/22)
Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%. More >

Three Analysts Like Healthcare Co.'s Upside
Source: Streetwise Reports  (7/11/22)
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care. More >

Pharma Looks To Improve Potential Psychedelic Stroke Drug
Source: Streetwise Reports  (7/11/22)
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September. More >

New Drug Is Shown to Help Stopped or Reduced Bile Flow
  (7/10/22)
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report. More >

New DMD Drug Yields 'Compelling' Data
  (7/9/22)
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report. More >

Amended Agreement to Benefit Two Biotech Firms
  (7/8/22)
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report. More >

Co. Makes Financing Deals Around Two of Its Approved Drugs
  (7/7/22)
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report. More >

Strong Data Suggest FDA Will Approve New Lymphoma Drug
  (7/6/22)
A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report. More >

The FDA Is Expected to Approve New Narcolepsy Drug
  (7/5/22)
Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report. More >

Trial of New Alzheimer's Drug Slated for Early 2023
  (7/1/22)
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report. More >

Chen's Top Picks for Q3
Source: Streetwise Reports  (6/30/22)
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter. More >

BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.
Source: Streetwise Reports  (6/30/22)
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses. More >

New Alzheimer's Drug Shows Promise as Monotherapy
  (6/29/22)
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report. More >

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains
Source: Streetwise Reports  (6/29/22)
Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins. More >

Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment
Source: Streetwise Reports  (6/28/22)
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates. More >

Approval Likely of New Gel for Skin Condition, Analyst Says
  (6/27/22)
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report. More >

EU Biopharma Co. Makes $247M Bid for US Oncology Co.
Source: Streetwise Reports  (6/27/22)
Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share. More >

Gene Therapy Co. Releases Data From Huntington's Study
Source: Streetwise Reports  (6/23/22)
Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial. More >

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial
Source: Streetwise Reports  (6/22/22)
Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial. More >

Results of Dermatitis Clinical Trial Due This Summer
  (6/21/22)
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report. More >

New Positive Data Seem to Support Drug Label Expansion
  (6/21/22)
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report. More >

New Drug for Heart Failure on Path to Approval, Analyst Says
  (6/20/22)
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.
More >

NFL Player Teams With Biopharma Co. to Help SCD Patients
Source: Streetwise Reports  (6/17/22)
Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease. More >